Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and ...

CEO Nello Mainolfi reflected on 2025 as "truly a breakout year" for Kymera, highlighting the progress of the first-in-class STAT6 degrader program. Mainolfi stated, "We shared outstanding results from ...

DENVER — New plans reveal more about how an ambitious project aims to remake a block of downtown Denver office space as a "vertical village" with apartments, restaurants and an art-filled public plaza ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...

Getting good at LeetCode Java isn’t just about solving problems; it’s about having a good plan. You need to know where to start, what tools to use, and how to keep going when things get tough. This ...

Kymera Therapeutics, Inc. reported robust Phase 1b results for KT-621, showing deep STAT6 degradation and strong clinical efficacy in atopic dermatitis. KT-621 demonstrated a favorable safety profile, ...

Plans to convert two mostly vacant downtown office towers at 621 and 633 17th Street to apartment buildings with affordable units are threatened by a standoff over a ground lease long held by the ...

Nadia Chaudhury is a born-and-raised New Yorker who is the deputy editor for Eater’s Northeast region and Eater New York, was the former Eater Austin editor for 10 years, and often writes about food ...